Ward Black Law is accepting cases of pancreatic, colorectal, or lung cancer in patients who took lorcaserin, better known as Belviq/Belviq XR, for weight management, after the U.S. Food & Drug Administration (FDA) requested a withdrawal of the medication due to the results of a clinical trial that showed an increased occurrence of cancer in Belviq users compared to those taking placebo.

Belviq was approved by the FDA in June, 2012 with an indication for weight loss in obese adults, defined as having a body mass index (BMI) of 30 or more, and for overweight adults, defined as having a BMI of 27 or more, with at least one comorbidity such as hypertension, hyperlipidemia, or type 2 diabetes, in combination with diet and exercise. The drug is also sold as an extended-release tablet called Belviq XR, which was approved July, 2016.

Upon its approval, the FDA required Eisai Inc., Belviq’s manufacturer, to conduct a trial to evaluate heart-related risks in adults taking Belviq (lorcaserin). The five-year trial studied 12,000 patients, and while it found no increased risks of heart-related complications, the trial revealed an elevated cancer incidence for the patients who had taken Belviq compared to those taking placebo. Pancreatic, colorectal, and lung cancer were specific cancers reported from the trial to have contributed to the greater number of cancer cases in Belviq-exposed patients compared to patients taking placebo.

The FDA urged patients to immediately stop taking the drug and ask their doctor for an alternative replacement.

Ward Black Law Can Help Patients Who Have Developed Cancer After Taking Belviq

Ward Black Law encourages any adult who has developed primary pancreatic, colorectal (colon or rectal), or lung cancer after taking Belviq/Belviq XR (lorcaserin) to contact the firm using the online form on this page or by calling or texting (800) 531-9191 for a free case review.